Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. CEO & Director Rob Brainin was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Mar 06
Champions Oncology, Inc. to Report Q3, 2026 Results on Mar 12, 2026 Champions Oncology, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026 Announcement • Dec 09
Champions Oncology, Inc. to Report Q2, 2026 Results on Dec 15, 2025 Champions Oncology, Inc. announced that they will report Q2, 2026 results After-Market on Dec 15, 2025 Announcement • Sep 12
Champions Oncology, Inc. to Report Q1, 2026 Results on Sep 15, 2025 Champions Oncology, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on Sep 15, 2025 Announcement • Aug 25
Champions Oncology, Inc., Annual General Meeting, Oct 16, 2025 Champions Oncology, Inc., Annual General Meeting, Oct 16, 2025. Location: one university plaza, suite 307, hackensack, newjersey 0760, United States Announcement • Jul 21
Champions Oncology, Inc. to Report Q4, 2025 Results on Jul 23, 2025 Champions Oncology, Inc. announced that they will report Q4, 2025 results After-Market on Jul 23, 2025 Announcement • Jul 09
Ch Champions Oncology Launches Radiopharmaceutical Services Platform Champions Oncology announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners. Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems. Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches. Announcement • Mar 12
Champions Oncology, Inc. Reaffirms Earnings Guidance for the Year 2025 Champions Oncology, Inc. reaffirmed earnings guidance for the year 2025. The company reaffirmed its full year revenue growth guidance of 10% to 15% and continue to focus on expanding its data business, enhancing profitability and driving shareholder value. Announcement • Mar 07
Champions Oncology, Inc. to Report Q3, 2025 Results on Mar 11, 2025 Champions Oncology, Inc. announced that they will report Q3, 2025 results After-Market on Mar 11, 2025 Announcement • Jan 09
Ch Champions Oncology, Inc. Enhances Clinical Bioanalytical Services Portfolio with New Technology Champions Oncology, Inc. announced significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of services will allow Champions to better serve its clients by offering increased depth through higher complexity spectral analysis. Announcement • Jan 08
Champions Oncology, Inc. Appoints Troy Tremaine to Spearhead Bioanalytical Commercial Strategy Champions Oncology, Inc. announced the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. the company is pleased to welcome Troy Tremaine, who will lead the commercial strategy for this growing business vertical. As a seasoned leader in this field, Troy brings decades of experience in commercial leadership within the preclinical and bioanalytical space, across multiple therapeutic areas. Announcement • Dec 06
Champions Oncology, Inc. to Report Q2, 2025 Results on Dec 11, 2024 Champions Oncology, Inc. announced that they will report Q2, 2025 results After-Market on Dec 11, 2024 Reported Earnings • Sep 12
First quarter 2025 earnings released: EPS: US$0.097 (vs US$0.19 loss in 1Q 2024) First quarter 2025 results: EPS: US$0.097 (up from US$0.19 loss in 1Q 2024). Revenue: US$14.1m (up 12% from 1Q 2024). Net income: US$1.31m (up US$3.88m from 1Q 2024). Profit margin: 9.3% (up from net loss in 1Q 2024). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Announcement • Sep 10
Champions Oncology, Inc. to Report Q1, 2025 Results on Sep 11, 2024 Champions Oncology, Inc. announced that they will report Q1, 2025 results After-Market on Sep 11, 2024 Announcement • Aug 28
Champions Oncology, Inc., Annual General Meeting, Oct 14, 2024 Champions Oncology, Inc., Annual General Meeting, Oct 14, 2024. Location: one university plaza, suite 307, hackensack, new jersey 07601, United States Reported Earnings • Jul 20
Full year 2024 earnings released: US$0.54 loss per share (vs US$0.39 loss in FY 2023) Full year 2024 results: US$0.54 loss per share (further deteriorated from US$0.39 loss in FY 2023). Revenue: US$50.2m (down 6.9% from FY 2023). Net loss: US$7.28m (loss widened 36% from FY 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Announcement • Jul 12
Champions Oncology, Inc. to Report Q4, 2024 Results on Jul 18, 2024 Champions Oncology, Inc. announced that they will report Q4, 2024 results After-Market on Jul 18, 2024 Reported Earnings • Mar 13
Third quarter 2024 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2023) Third quarter 2024 results: US$0.19 loss per share (further deteriorated from US$0.18 loss in 3Q 2023). Revenue: US$12.0m (down 5.9% from 3Q 2023). Net loss: US$2.53m (loss widened 3.7% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Announcement • Mar 07
Champions Oncology, Inc. to Report Q3, 2024 Results on Mar 12, 2024 Champions Oncology, Inc. announced that they will report Q3, 2024 results After-Market on Mar 12, 2024 New Risk • Dec 22
New major risk - Revenue and earnings growth Earnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (€60.6m market cap, or US$66.7m). Reported Earnings • Dec 13
Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.001 loss in 2Q 2023) Second quarter 2024 results: US$0.15 loss per share (further deteriorated from US$0.001 loss in 2Q 2023). Revenue: US$11.6m (down 19% from 2Q 2023). Net loss: US$2.07m (loss widened US$2.06m from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Announcement • Dec 05
Champions Oncology, Inc. to Report Q2, 2024 Results on Dec 12, 2023 Champions Oncology, Inc. announced that they will report Q2, 2024 results After-Market on Dec 12, 2023 Announcement • Oct 18
Champions Oncology, Inc. Appoints Brady Davis as President Champions Oncology, Inc. has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth. Mr. Davis brings more than 25 years of international experience leading medical instrument, software, data, and services companies in the healthcare space. As an executive leader, he has advanced commercial, product/market development, marketing, and bioinformatics teams in both established (Hewlett Packard, Oracle, Illumina) and developing (DNAnexus, Canexia Health) companies. Mr. Davis will be collaborating with the executive team including the commercial and scientific teams to explore strategies to accelerate growth, both organically and in-organically. Recent Insider Transactions • Sep 26
Independent Director recently bought €91k worth of stock On the 22nd of September, Daniel Mendelson bought around 18k shares on-market at roughly €5.11 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €138k more in shares than they have sold in the last 12 months. Reported Earnings • Sep 14
First quarter 2024 earnings released: US$0.19 loss per share (vs US$0.024 loss in 1Q 2023) First quarter 2024 results: US$0.19 loss per share (further deteriorated from US$0.024 loss in 1Q 2023). Revenue: US$12.6m (down 8.6% from 1Q 2023). Net loss: US$2.57m (loss widened US$2.25m from 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Announcement • Sep 12
Champions Oncology, Inc. to Report Q1, 2024 Results on Sep 13, 2023 Champions Oncology, Inc. announced that they will report Q1, 2024 results on Sep 13, 2023 Announcement • Aug 29
Champions Oncology, Inc., Annual General Meeting, Oct 19, 2023 Champions Oncology, Inc., Annual General Meeting, Oct 19, 2023, at 09:00 US Eastern Standard Time. Location: the Company’s headquarters, located at One University Plaza, Suite 307, Hackensack, New Jersey 07601 New Jersey United States Agenda: To discuss elect the seven board of director nominees named in the accompanying proxy statement to the board of directors for the ensuring year and until his successor has been elected and qualified, or until his earlier death, resignation or removal; to discuss ratify the appointment of eisneramper llp as our independent registered public accounting firm for the fiscal year ending april 30, 2024; to approve a non-binding advisory resolution relating to the compensation of our named executive officers; and to discuss transact such other business. New Risk • Jul 25
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (€78.1m market cap, or US$86.3m). Reported Earnings • Jul 25
Full year 2023 earnings released: US$0.39 loss per share (vs US$0.042 profit in FY 2022) Full year 2023 results: US$0.39 loss per share (down from US$0.042 profit in FY 2022). Revenue: US$53.9m (up 9.7% from FY 2022). Net loss: US$5.34m (down US$5.88m from profit in FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Jul 23
Champions Oncology, Inc. to Report Q4, 2023 Results on Jul 24, 2023 Champions Oncology, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Jul 24, 2023 New Risk • Jul 06
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$64k net loss next year). Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (€78.6m market cap, or US$85.3m). Reported Earnings • Mar 17
Third quarter 2023 earnings released: US$0.18 loss per share (vs US$0.058 profit in 3Q 2022) Third quarter 2023 results: US$0.18 loss per share (down from US$0.058 profit in 3Q 2022). Revenue: US$12.8m (down 3.2% from 3Q 2022). Net loss: US$2.44m (down 410% from profit in 3Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 15
Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.021 profit in 2Q 2022) Second quarter 2023 results: US$0.001 loss per share (down from US$0.021 profit in 2Q 2022). Revenue: US$14.3m (up 21% from 2Q 2022). Net loss: US$16.0k (down 106% from profit in 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Dec 10
Champions Oncology, Inc. to Report Q2, 2023 Results on Dec 13, 2022 Champions Oncology, Inc. announced that they will report Q2, 2023 results After-Market on Dec 13, 2022 Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. Independent Director Rob Brainin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 10
First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.013 loss in 1Q 2022) First quarter 2023 results: US$0.024 loss per share (further deteriorated from US$0.013 loss in 1Q 2022). Revenue: US$13.7m (up 22% from 1Q 2022). Net loss: US$319.0k (loss widened 86% from 1Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Sep 07
Champions Oncology, Inc. to Report Q1, 2023 Results on Sep 08, 2022 Champions Oncology, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on Sep 08, 2022 Announcement • Sep 01
Champions Oncology, Inc., Annual General Meeting, Oct 20, 2022 Champions Oncology, Inc., Annual General Meeting, Oct 20, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider elect the seven board of director nominees named in the accompanying proxy statement to the board of directors for the ensuing year and until his successor has been elected and qualified, or until his earlier death, resignation or removal; to ratify the appointment of eisneramper llp as independent registered public accounting firm for the fiscal year ending April 30, 2023; to approve a non-binding advisory resolution relating to the compensation of named executive officers; and to consider other matter. Reported Earnings • Jul 23
Full year 2022 earnings released: EPS: US$0.042 (vs US$0.028 in FY 2021) Full year 2022 results: EPS: US$0.042 (up from US$0.028 in FY 2021). Revenue: US$49.1m (up 20% from FY 2021). Net income: US$548.0k (up 51% from FY 2021). Profit margin: 1.1% (up from 0.9% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 14% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Board Change • Apr 29
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. Independent Director Rob Brainin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 17
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2022 results: EPS: US$0.058 (up from US$0.055 in 3Q 2021). Revenue: US$13.2m (up 22% from 3Q 2021). Net income: US$787.0k (up 6.4% from 3Q 2021). Profit margin: 6.0% (down from 6.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.8%. Over the next year, revenue is forecast to grow 17%, compared to a 23% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 15
First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.006 profit in 1Q 2021) The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$11.3m (up 18% from 1Q 2021). Net loss: US$172.0k (down 329% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 24
Full year 2021 earnings released: EPS US$0.025 (vs US$0.17 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$41.0m (up 28% from FY 2020). Net income: US$334.0k (up US$2.31m from FY 2020). Profit margin: 0.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 13
Revenue beats expectations Revenue exceeded analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 17%, compared to a 21% growth forecast for the Life Sciences industry in Germany. Reported Earnings • Mar 13
Third quarter 2021 earnings released: EPS US$0.055 (vs US$0.035 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$10.8m (up 20% from 3Q 2020). Net income: US$740.0k (up 82% from 3Q 2020). Profit margin: 6.8% (up from 4.5% in 3Q 2020). Is New 90 Day High Low • Mar 04
New 90-day high: €10.00 The company is up 16% from its price of €8.65 on 04 December 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €18.69 per share. Executive Departure • Feb 16
Independent Director has left the company On the 8th of February, Abba Poliakoff's tenure as Independent Director ended after 13.0 years in the role. As of December 2020, Abba personally held 60.15k shares (€529k worth at the time). Abba is the only executive to leave the company over the last 12 months. Announcement • Feb 13
Champions Oncology, Inc. Announces Resignation of Abba David Poliakoff as Board of Director Abba David Poliakoff informed the Board of Directors of Champions Oncology, Inc. of his intention to resign as a director of the company effective immediately. His resignation was for personal reasons and was not due to any disagreement with the company. To fill the vacancy created by Mr. Poliakoff's resignation, on February 8, 2021, the Board appointed Robert Brainin to serve as a member of the Board, effective immediately. Mr. Brainin has over 15 years of experience in the global life sciences and healthcare fields. He was most recently the Chief Executive Officer of Genuity Science from March 2018 to January 2021, also serving as a director from June 2020 until January 2021. Recent Insider Transactions • Dec 18
Board Member recently sold €293k worth of stock On the 16th of December, Philip Breitfeld sold around 31k shares on-market at roughly €9.32 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €286k more than they bought in the last 12 months. Announcement • Dec 16
Champions Oncology, Inc. Revises Revenue Guidance for the Year 2021 Champions Oncology, Inc. revised revenue guidance for the year 2021. The company raising full-year revenue guidance to 20%-25%. Analyst Estimate Surprise Post Earnings • Dec 16
Revenue beats expectations Revenue exceeded analyst estimates by 7.8%. Over the next year, revenue is forecast to grow 14%, compared to a 18% growth forecast for the Life Sciences industry in Germany. Is New 90 Day High Low • Nov 13
New 90-day high: €8.30 The company is up 6.0% from its price of €7.85 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.10 per share. Announcement • Jul 03
Champions Oncology, Inc.(NasdaqCM:CSBR) dropped from Russell Microcap Value Index Champions Oncology, Inc.(NasdaqCM:CSBR) dropped from Russell Microcap Value Index 
